KKR agrees $2.3bn pharmaceutical carve-out

The firm, which has agreed to buy Pfizer’s hard capsule manufacturer Capsugel, has completed numerous healthcare-related deals and also has ‘significant’ experience with ‘carve out’ deals.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this